Serban San-Marina

Serban has a thorough understanding of cellular and molecular biology acquired through painstaking experimental science practice. He has intimate familiarity with complex protocols, whether involving animal experimentation or proteomic/genomic analyses. As such he understands novelty as well as feasibility of discovery/validation protocols and is able to make timely and informed ‘go/no go’ decisions. He has also honed his passion for coding and computational analysis into IT products that predict drug activity and synergy. He brings to Jellagen a well-rounded biomedical and experimental perspective from both academic and industry vantage points that will suit Jellagen well in its quest to become a premiere marine biology company.

Dr. Serban San-Marina completed undergraduate and graduate studies at the University of Toronto, Medical studies at the Carol Davila School of Medicine in Bucharest, Romania and holds a PhD in Biology from York University, Toronto, Canada. He completed Post-doctoral fellowships at Penn State in T-cell Immunobiology and at the Ontario Cancer Institute in Leukemia Transcription Factor Research. In 2006, he co-founded Biostatistix for repurposed drug discovery. Using computational analysis and experimental validation he identified MoA’s for new compounds. One compound is currently in an FDA clinical trial for gynecological malignancies. He joined the Mayo Clinic in 2013 where his interests are in new biomaterials and biologicals for regenerative medicine and small molecule-directed stem cell reprogramming.